Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Verastem Oncology (NASDAQ: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced its 2025 priorities and upcoming ...

Verastem, Inc. (NASDAQ: VSTM) recently disclosed in an 8-K filing with the Securities and Exchange Commission that on January 13, 2025, the company entered into a Note Purchase Agreement with RGCM SA ...

NEEDHAM, MA - Verastem, Inc. (NASDAQ:VSTM), a $247.5 million market cap biopharmaceutical company focused on developing and ...

V2X, Inc., , a leading provider of global mission solutions, will report fourth quarter and full year 2024 financial results on Monday, February 24, 2025, after market close. Senior management will ...

MSTRO, a privately owned company, redefining human potential by revolutionizing how we reason through data, is proud to announce the successful completion of a $1.5 million seed funding round. This ...

BTIG analyst Justin Zelin reiterated a Buy rating on Viking Therapeutics (VKTX – Research Report) yesterday and set a price target of ...

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%. Verastem (VSTM) doses the ...

In a report released on January 17, Sean Lee from Citi reiterated a Buy rating on Innate Pharma (IPHA – Research Report), with a price target ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...